Johnson and Johnson 2005 Annual Report Download - page 14

Download and view the complete annual report

Please find page 14 of the 2005 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 80

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80

PAGE 12 JOHNSON & JOHNSON 2005 ANNUAL REPORT
The breadth of scientific knowledge and capabilities across
our businesses give Johnson & Johnson companies
unparalleled opportunities to collaborate and pursue
breakthroughs. Building upon the success of DePuy
Biologics, a new center of excellence is expanding the
scope of regenerative medicine activities from musculo-
skeletal products into new therapeutic areas. The group
is investigating the potential of transformational
technologies such as cell therapy, novel biomaterials,
bioactive proteins, and combinations of these, to
address diseases and conditions in orthopaedics, urology,
gynecology, neurology and cardiovascular medicine.
Similarly,work is underway between Veridex, LLC and
Johnson & Johnson Pharmaceutical Research &
Development, L.L.C. to identify biomarkers and establish
data on how an individual’s genetics affect the body’s
response to drugs.
Commitment to growth in the emerging cardiovascular platform
is represented on many fronts. In a collaboration for
the prevention and treatment of thrombosis, Scios Inc.,
Ortho-McNeil Pharmaceutical, Inc. and Bayer HealthCare
will jointly develop and market BAY 59-7939 (Factor Xa
Expansion of scientific capabilities and the convergence of
technologies broaden the therapeutic benefits of existing products
and deliver novel treatment options for complex diseases.
Left: Centocor Biologics (Ireland)
Limited, the biomedicine manufac-
turing facility under construction
in County Cork, Ireland, represents
another significant investment for
Johnson & Johnson in this region.
Targeted to be fully operational by
2010, the state-of-the-art facility
will produce products for immun-
ology pioneer Centocor, Inc. for
the treatment of immune-mediated
inflammatory disorders.
inhibitor), in development for venous thromboembolism
(VTE) prevention after major orthopaedic surgery, venous
thromboembolism treatment and stroke prevention
in atrial fibrillation. Phase III studies in VTE prevention
after major orthopaedic surgery have been initiated.
If the compound is approved, Scios and Ortho-McNeil
Pharmaceutical will share exclusive marketing rights
for the cardiology, primary care and hospital specialty
markets in the U.S. Bayer will have an option to co-
promote the drug in U.S. hospital and specialty markets,
and will have sole marketing rights in other countries.
REMICADE® (infliximab) continues to achieve unprecedented
milestones in the treatment of immune-mediated inflam-
matory diseases. REMICADE®from Centocor, Inc.
received approvals in the U.S. in the treatment of psori-
atic arthritis and is the first and only biologic approved
in the treatment of ulcerative colitis (UC), a chronic
inflammatory bowel disease. REMICADE®also was
approved in the European Union for the treatment of
moderate to severe plaque psoriasis, a chronic, immune-
mediated disease caused when skin cells over-produce
and accumulate on the surface, causing itchy, scaly